Bio-Rad Laboratories, Inc. (NYSE: BIO) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 45.63 | EPS (ttm) | 8.25 | Insider Own | 8.82% | Shs Outstand | 26.92M | Perf Week | 1.92% |
| Market Cap | 10.11B | Forward P/E | 36.38 | EPS next Y | 10.35 | Insider Trans | -0.02% | Shs Float | 17.88M | Perf Month | 3.34% |
| Enterprise Value | 9.72B | PEG | 4.66 | EPS next Q | 2.23 | Inst Own | - | Short Float | 6.32% | Perf Quarter | 33.27% |
| Income | 222.00M | P/S | 3.91 | EPS this Y | 16.85% | Inst Trans | - | Short Ratio | 3.68 | Perf Half Y | 42.04% |
| Sales | 2.59B | P/B | 1.41 | EPS next Y | 7.34% | ROA | 2.17% | Short Interest | 1.13M | Perf YTD | 24.23% |
| Book/sh | 266.53 | P/C | 6.26 | EPS next 5Y | 9.80% | ROE | 3.15% | 52W High | 396.22 -5.00% | Perf Year | 34.29% |
| Cash/sh | 60.15 | P/FCF | 28.15 | EPS past 3/5Y | - -26.07% | ROIC | 1.54% | 52W Low | 236.74 59.00% | Perf 3Y | 2.12% |
| Dividend Est. | - | EV/EBITDA | 18.20 | Sales past 3/5Y | -2.68% 0.29% | Gross Margin | 51.90% | Volatility | 2.46% 2.75% | Perf 5Y | -54.10% |
| Dividend TTM | - | EV/Sales | 3.75 | EPS Y/Y TTM | 112.62% | Oper. Margin | 9.08% | ATR (14) | 10.09 | Perf 10Y | 134.71% |
| Dividend Ex-Date | - | Quick Ratio | 2.33 | Sales Y/Y TTM | 0.86% | Profit Margin | 8.59% | RSI (14) | 55.49 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.14 | EPS Q/Q | 0.38% | SMA20 | -1.30% | Beta | 1.06 | Target Price | 350.00 |
| Payout | 22.03% | Debt/Eq | 0.21 | Sales Q/Q | -0.15% | SMA50 | 7.32% | Rel Volume | 1.10 | Prev Close | 382.41 |
| Employees | 7,450 | LT Debt/Eq | 0.20 | Earnings | Oct 29 | SMA200 | 23.58% | Avg Volume | 293.66K | Price | 376.41 |
| IPO Date | Feb 27, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 49.92% 4.33% | Net Debt/EBITDA | 1.28 | Volume | 324,345 | Change | -1.57% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | RBC Capital | Outperform | $370 → $390 |
| Aug-05-26 | Reiterated | RBC Capital | Outperform | $320 → $370 |
| May-25-26 | Reiterated | Wells Fargo | Equal Weight | $290 → $310 |
| May-14-26 | Resumed | RBC Capital | Outperform | $565 → $320 |
| May-01-26 | Reiterated | Wells Fargo | Equal Weight | $320 → $290 |
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral | |
| Feb-16-26 | Reiterated | Wells Fargo | Equal Weight | $340 → $320 |
| Feb-13-26 | Reiterated | UBS | Buy | $350 → $335 |
| Oct-30-25 | Reiterated | Wells Fargo | Equal Weight | $340 |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy | $400 |
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,589 | 2,583 | 2,567 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,246 | 1,240 | 1,188 | — | — | — | — | — | — | |
| Gross Profit | 1,343 | 1,344 | 1,379 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 848 | 820 | 814 | — | — | — | — | — | — | |
| Research and Development | 261 | 257 | 296 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 1 | 0 | — | — | — | — | — | — | |
| Operating Income | 235 | 271 | 269 | — | — | — | — | — | — | |
| Interest Expense | 36 | 49 | 49 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 152 | 774 | -2,563 | — | — | — | — | — | — | |
| Net Income Before Taxes | 350 | 996 | -2,342 | — | — | — | — | — | — | |
| Income Taxes | 128 | 236 | -498 | — | — | — | — | — | — | |
| Consolidated Net Income | 222 | 760 | -1,844 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 222 | 760 | -1,844 | — | — | — | — | — | — | |
| Net Income | 222 | 760 | -1,844 | — | — | — | — | — | — | |
| EPS (Recurring) | 8.33 | 27.87 | -65.36 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 8.33 | 27.87 | -65.36 | — | — | — | — | — | — | |
| EPS (Diluted) | 8.25 | 27.87 | -65.36 | — | — | — | — | — | — | |
| EBITDA | 534 | 1,250 | -2,142 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 45.63 | 10.87 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.93 | 3.17 | 3.58 | — | — | — | — | — | — | |
| Gross Margin | 51.87 | 52.03 | 53.72 | — | — | — | — | — | — | |
| Operating Margin | 9.08 | 10.49 | 10.48 | — | — | — | — | — | — | |
| Net Margin | 8.57 | 29.42 | -71.83 | — | — | — | — | — | — | |
| Shares Outstanding | 27 | 27 | 28 | — | — | — | — | — | — | |
| Market Capitalization | 10,163 | 8,181 | 9,198 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Sep 06 '26 | Option Exercise | 0.00 | 1,536 | 0 | 4,933 | Sep 09 |
| SCHWARTZ NORMAN D | Chairman & CEO | Sep 06 '26 | Option Exercise | 0.00 | 3,455 | 0 | 450,873 | Sep 09 |
| BARRY JAMES | EVP, President, LSG | Sep 06 '26 | Option Exercise | 0.00 | 1,056 | 0 | 2,495 | Sep 09 |
| Allison Schwartz | Director | Sep 06 '26 | Option Exercise | 0.00 | 92 | 0 | 1,768 | Sep 09 |
| ENLOE COURTNEY C | EVP, General Counsel & Sec | Sep 06 '26 | Option Exercise | 0.00 | 768 | 0 | 1,957 | Sep 09 |
| EVRAN SEDAT | EVP, Global Supply Chain | Sep 06 '26 | Option Exercise | 0.00 | 864 | 0 | 3,880 | Sep 09 |
| ENGELHARDT EVA ANETTE | EVP, President, CDG | Sep 06 '26 | Option Exercise | 0.00 | 1,152 | 0 | 2,313 | Sep 09 |
| EVRAN SEDAT | EVP, Global Supply Chain | Sep 05 '26 | Option Exercise | 0.00 | 1,027 | 0 | 3,345 | Sep 09 |
| DiVincenzo Jonathan P. | President & COO | Sep 05 '26 | Option Exercise | 0.00 | 1,712 | 0 | 2,631 | Sep 09 |
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Sep 05 '26 | Option Exercise | 0.00 | 1,370 | 0 | 3,956 | Sep 09 |
| Mehta Rajat | EVP, GBL Commercial Operations | Sep 05 '26 | Option Exercise | 0.00 | 1,826 | 0 | 1,736 | Sep 09 |
| SCHWARTZ NORMAN D | Chairman & CEO | Sep 05 '26 | Option Exercise | 0.00 | 4,109 | 0 | 450,294 | Sep 09 |
| Allison Schwartz | Director | Sep 05 '26 | Option Exercise | 0.00 | 228 | 0 | 1,758 | Sep 09 |
| ENGELHARDT EVA ANETTE | EVP, President, CDG | Sep 05 '26 | Option Exercise | 0.00 | 1,027 | 0 | 1,530 | Sep 09 |
| ENLOE COURTNEY C | EVP, General Counsel & Sec | Sep 05 '26 | Option Exercise | 0.00 | 685 | 0 | 1,435 | Sep 09 |